$1.07 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter

Analysts forecast that ABIOMED, Inc. (NASDAQ:ABMD) will announce $1.07 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for ABIOMED’s earnings, with the lowest EPS estimate coming in at $1.03 and the highest estimate coming in at $1.13. ABIOMED posted earnings per share of $0.80 in the same quarter last year, which would indicate a positive year-over-year growth rate of 33.8%. The firm is expected to announce its next earnings results on Thursday, May 2nd.

According to Zacks, analysts expect that ABIOMED will report full year earnings of $5.05 per share for the current fiscal year, with EPS estimates ranging from $4.97 to $5.09. For the next fiscal year, analysts anticipate that the business will report earnings of $4.94 per share, with EPS estimates ranging from $4.73 to $5.44. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow ABIOMED.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.03. ABIOMED had a net margin of 30.12% and a return on equity of 20.31%. The firm had revenue of $200.56 million for the quarter, compared to analysts’ expectations of $200.60 million.

Several brokerages have issued reports on ABMD. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $370.00 target price on the stock in a research note on Friday, January 18th. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a research note on Friday, December 28th. ValuEngine cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Wednesday, February 27th. Finally, Morgan Stanley lowered their target price on shares of ABIOMED from $496.00 to $461.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 2nd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. ABIOMED currently has an average rating of “Buy” and a consensus target price of $421.00.

ABMD traded up $1.69 on Friday, hitting $285.59. 763,917 shares of the company’s stock were exchanged, compared to its average volume of 578,611. ABIOMED has a fifty-two week low of $272.17 and a fifty-two week high of $459.75. The stock has a market cap of $12.88 billion, a PE ratio of 116.57, a price-to-earnings-growth ratio of 2.86 and a beta of 0.37.

In related news, COO David M. Weber sold 24,000 shares of the business’s stock in a transaction dated Friday, January 25th. The shares were sold at an average price of $351.47, for a total value of $8,435,280.00. Following the sale, the chief operating officer now directly owns 161,842 shares in the company, valued at approximately $56,882,607.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Martin P. Sutter sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $360.00, for a total transaction of $1,800,000.00. Following the completion of the sale, the director now owns 195,491 shares in the company, valued at $70,376,760. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,928 shares of company stock worth $26,515,812. 3.50% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of ABMD. Sontag Advisory LLC purchased a new stake in ABIOMED during the fourth quarter worth about $25,000. We Are One Seven LLC purchased a new stake in ABIOMED during the fourth quarter worth about $26,000. Cornerstone Advisors Inc. increased its stake in ABIOMED by 304.8% during the fourth quarter. Cornerstone Advisors Inc. now owns 85 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 64 shares during the period. Shine Investment Advisory Services Inc. increased its stake in ABIOMED by 319.0% during the fourth quarter. Shine Investment Advisory Services Inc. now owns 88 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 67 shares during the period. Finally, Captrust Financial Advisors increased its stake in ABIOMED by 1,187.5% during the fourth quarter. Captrust Financial Advisors now owns 103 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 95 shares during the period. Hedge funds and other institutional investors own 87.92% of the company’s stock.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: What is insider trading?

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.